279P Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01)

• DOI: 10.1016/j.annonc.2021.08.562
• Publication Date: 2021-09-21T18:45:52Z
• Authors: C. Saura Manich; S. Modi; I. Krop; Y.H. Park; S-B. Kim; K. Tamura; F. André; H. Iwata; Y. Ito; J. Tsurutani; J. Sohn; C. Lee; Y. Liu; J. Cathcart; J. Singh; T. Yamashita
• Keywords: Clinical endpoint